{"preliminary_commentary":{"by_channel":{"youtube":6,"x_thread":5,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03836209\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT03836209","nct_id":"NCT03836209","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03836209. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.\n\nConsolidation: High-dose cytarabine and gilteritinib.","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.\n\nConsolidation: High-dose cytarabine and midostaurin.","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":["Astellas Pharma Inc"],"completion_date":{"date":"2026-06-30","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia"],"enrollment":{"count":181,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Gilteritinib","otherNames":["ASP2215"],"type":"DRUG"},{"name":"Midostaurin","otherNames":["RYDAPT"],"type":"DRUG"},{"name":"Daunorubicin","otherNames":["Daunorubicin hydrochloride","Daunomycin","Rubidomycin","Cerubidine"],"type":"DRUG"},{"name":"Cytarabine","otherNames":["Cytosar-U","Ara-C","Arabinosyl","Cytosine Arabinoside"],"type":"DRUG"}],"last_update":"2026-07-23","lead_sponsor":"PrECOG, LLC.","official_title":"Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-10-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"FLT3 Mutation Negative Composite Complete Response (CRc) [Includes Complete Response (CR) or CR With Incomplete Hematologic Recovery (CRi)] at End of Induction","timeFrame":"3 months"}],"references":[],"start_date":{"date":"2019-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia","url":"https://clinicaltrials.gov/study/NCT03836209"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03836209"}